Transmission dynamics of the M184V drug resistance mutation in primary HIV infection.
暂无分享,去创建一个
[1] K. Metzner,et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. , 2011, JAMA.
[2] D. Pillay,et al. Increased detection of the HIV‐1 reverse transcriptase M184V mutation using mutation‐specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance * , 2011, HIV medicine.
[3] M. Wainberg,et al. Detection of Human Immunodeficiency Virus (HIV) Type 1 M184V and K103N Minority Variants in Patients with Primary HIV Infection , 2009, Antimicrobial Agents and Chemotherapy.
[4] Michel Roger,et al. Transmission networks of drug resistance acquired in primary/early stage HIV infection , 2008, AIDS.
[5] Michael Monsour,et al. Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.
[6] D. Pillay,et al. Prevalence of Transmitted HIV-1 Drug Resistance and the Role of Resistance Algorithms: Data From Seroconverters in the CASCADE Collaboration From 1987 to 2003 , 2005, Journal of acquired immune deficiency syndromes.
[7] K. Metzner,et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. , 2003, The Journal of infectious diseases.
[8] Bluma G. Brenner,et al. Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary Infection , 2002, Journal of Virology.
[9] M. D. De Pasquale,et al. Loss of Lamivudine Resistance in a Zidovudine and Lamivudine Dual-Resistant HIV-1 Isolate after Discontinuation of In Vitro Lamivudine Drug Pressure , 1998, Antiviral therapy.
[10] G. Shaw,et al. Extensive variation of human immunodeficiency virus type-1 in vivo , 1988, Nature.